PHARMACEUTICAL PREPARATIONS FOR ADDICTION TREATMENT

承包商应作为药物配方资源，以支持 临床前药理学/毒理学评价和临床试验。 简而言之，本合同的目标是确定实物 以及药物物质的化学特性来开发该物质 变成临床上有用的配方。它涉及到识别化学物质 药物的特性及其与各种溶剂的配伍性， 试剂和非活性成分及其环境稳定性 条件(例如，光、温度、湿度)。配方必须是 与预定的给药途径相适应，该药物的 给药时的代谢及其在临床上实现的能力 有效组织/目标浓度。患者遵从性问题，例如： 每种用途；给药频率和途径；以及改用于 在配制新的剂量或新的剂量时，也必须考虑非法使用 毒品物质。本合同产生的数据和产品将是 被NIDA药物开发部(MDD)用于开发 以及检测药物制剂在药物治疗中的作用 上瘾。

The Contractor shall serve as a drug formulations resource in support of preclinical pharmacological/toxicological evaluations and clinical trials. In brief, the objectives of this contract are to determine the physical and chemical characteristics of a drug substance to develop the substance into clinically useful formulations. It involves identifying the chemical characteristics of the drug and its compatibility with various solvents, reagents and inactive ingredients, and its stability to environmental conditions (e.g., light, temperature, humidity). The formulation must be compatible with the route of administration intended, the drug's metabolism upon administration and its ability to achieve a clinically effective tissue/target concentration. Patient compliance issues, such as: each of use; frequency and route of administration; and diversion to illegal use must also be considered when formulating a new dosage or a new drug substance. The data and products generated by this contract will be utilized by the NIDA Medications Development Division (MDD) in developing and testing pharmaceutical preparations in the treatment of drug addictions.